CLC Number:
| [1] |
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: Prevalence, incidence, treatment patterns and risk factors[J]. Nat Rev Rheumatol, 2020, 16(7):380-390.
doi: 10.1038/s41584-020-0441-1 pmid: 32541923 |
| [2] |
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout[J]. Arthritis Rheumatol, 2020, 72(6):879-895.
doi: 10.1002/art.v72.6 |
| [3] |
Dalbeth N, Gosling AL, Gaffo A, et al. Gout[J]. Lancet, 2021, 397(10287):1843-1855.
doi: 10.1016/S0140-6736(21)00569-9 pmid: 33798500 |
| [4] |
Dalbeth N, Jones G, Terkeltaub R, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout[J]. Arthritis Rheumatol, 2017, 69(9):1903-1913.
doi: 10.1002/art.40159 |
| [5] |
Khanna PP, Khanna D, Cutter G, et al. Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: A phase Ⅱ, randomized, double-blind, placebo-controlled trial[J]. Arthritis Rheumatol, 2021, 73(8):1523-1532.
doi: 10.1002/art.v73.8 |
| [6] |
White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout[J]. N Engl J Med, 2018, 378(13):1200-1210.
doi: 10.1056/NEJMoa1710895 |
| [7] |
Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial[J]. Lancet, 2020, 396(10264):1745-1757.
doi: 10.1016/S0140-6736(20)32234-0 pmid: 33181081 |
| [1] | WANG Gui-hong,ZUO Ting,LI Ran,ZUO Zheng-cai. Effect of rebamipide on the acute gouty arthritis in rats induced by monosodium urate crystals [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 716-720. |
| [2] | XIE Yi-fan,WANG Yu,DENG Xue-rong,GENG Yan,JI Lan-lan,ZHANG Zhuo-li. Analysis of risk factors influencing the detection rate of urate crystal by dual energy computed tomography [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 261-265. |
| [3] | WANG Yu,DENG Xue-rong,JI Lan-lan,ZHANG Xiao-hui,GENG Yan,ZHANG Zhuo-li. Risk factors and diagnostic value for ultrasound-detected tendon monosodium urate crystal deposition in patients with gout [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 143-149. |
| [4] | ZHANG Qian-ru, WANG Yu, ZHANG Zhuo-li. Performance of the 2015 ACR/EULAR classification criteria compared with other classification criteria for diagnosis of gout in Chinese patients [J]. Journal of Peking University(Health Sciences), 2017, 49(6): 979-984. |
|